Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830964 | 0.81 | MAPK1 (0.36) | MAPK1ATMCHRM1MEN1USP2 | |
| SCHEMBL1441383 | 0.79 | MAPK1 (0.38) | MAPK1ATMCHRM1MEN1USP2 | |
| SCHEMBL11830952 | 0.78 | CHRM1 (0.33) | CHRM1 | |
| SCHEMBL11830450 | 0.78 | — | — | |
| SCHEMBL11775749 | 0.78 | — | — | |
| SCHEMBL11831678 | 0.78 | — | — | |
| SCHEMBL11735795 | 0.78 | MAPK1 (0.32) | MAPK1ATMNPC1MAPTMEN1 | |
| SCHEMBL5045818 | 0.77 | MAPK1 (0.34) | MAPK1ATM | |
| SCHEMBL11384100 | 0.75 | NPC1 (0.35) | NPC1MAPTMEN1KMT2A | |
| SCHEMBL11750132 | 0.74 | CHRM1 (0.35) | MAPK1ATMCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1083355-A | The local drug delivery film that is used for the treatment of periodontal disease | DONG KOOK PHARM CO LTD (KR) | 1994-03-09 | — | — | CN | claimed |
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO- CLINIC" (NL) | 2015-06-04 | — | — | US | disclosed |
| US-8980932-B2 | Cancer targeting using carbonic anhydrase isoform IX inhibitors | Stichting Maastricht Radiation Oncology “Maastro-Clinic” (NL) | 2015-03-17 | — | — | US | disclosed |
| EP-2655336-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO CLINIC" (NL) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | Supuran, Claudiu (IT) | 2013-10-17 | — | — | US | disclosed |
| WO-2012087115-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC" (NL) | 2012-06-28 | — | — | WO | disclosed |
| CN-1656096-A | Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2005-08-17 | — | — | CN | disclosed |
| CN-1034078-C | Boronic acid adducts of rhenium dioxime and technetium-99M dioxime complexes containing biochemically active groups | BURA SCIENCE AND TECH INTERNAT (US) | 1997-02-19 | — | — | CN | disclosed |
| CN-1133354-A | Biological pollution control for oil field | ROHM & HAAS (US) | 1996-10-16 | — | — | CN | disclosed |
| CN-1111621-A | Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group | SQUIBB & SONS INC (US) | 1995-11-15 | — | — | CN | disclosed |
| CN-1093084-A | The rhenium and the technetium complex that comprise the anoxic localization part | SQUIBB & SONS INC (US) | 1994-10-05 | — | — | CN | disclosed |
| CN-1083355-A | The local drug delivery film that is used for the treatment of periodontal disease | DONG KOOK PHARM CO LTD (KR) | 1994-03-09 | — | — | CN | disclosed |
| CN-1021052-C | 8-ALKOXYQUINOLONECAR BOXYLIC ACID AND SALTS THEREOF EXCELLENT IN SELECTIVE TOXICITY AND PROCESS OF PREPARING SAME | KYORIN SEIYAKU KK (JP) | 1993-06-02 | — | — | CN | disclosed |
| CN-1071928-A | The rhenium and the technetium complex that comprise the anoxic localization part | SQUIBB & SONS INC (US) | 1993-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | MAPK1 3753/4885ATM 2675/4885CHRM1 2408/4885 |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | MAPK1 2993/4885ATM 2783/4885CHRM1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.